Top Page
Jaguar Animal Health
(NASDAQ:JAGX)
Jaguar Animal Health (JAGX) vs. SPDR S&P 500 ETF (SPY)
Jaguar Animal Health Business Overview & Revenue Model
Jaguar Animal Health Earnings Call Summary
Jaguar Animal Health Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.77M | 11.69M | 9.76M | 11.96M | 4.33M | 9.38M |
| Gross Profit | 9.67M | 9.73M | 7.72M | 9.94M | 2.00M | 6.11M |
| EBITDA | -39.29M | -36.66M | -33.13M | -33.38M | -42.35M | -28.74M |
| Net Income | -40.65M | -38.49M | -41.30M | -47.45M | -60.25M | -36.79M |
Balance Sheet | ||||||
| Total Assets | 48.27M | 53.42M | 50.76M | 47.45M | 53.27M | 42.84M |
| Cash, Cash Equivalents and Short-Term Investments | 2.21M | 8.00M | 6.47M | 5.47M | 17.05M | 8.09M |
| Total Debt | 30.53M | 36.53M | 37.09M | 34.84M | 29.36M | 16.21M |
| Total Liabilities | 41.39M | 46.93M | 45.87M | 48.81M | 41.41M | 25.64M |
| Stockholders Equity | 7.99M | 9.77M | 4.96M | -657.00K | 11.61M | 17.20M |
Cash Flow | ||||||
| Free Cash Flow | -27.88M | -29.61M | -33.24M | -34.78M | -34.98M | -15.29M |
| Operating Cash Flow | -27.68M | -29.38M | -33.24M | -33.10M | -34.97M | -15.28M |
| Investing Cash Flow | -215.00K | -231.00K | 1.23M | -1.68M | -6.00K | -7.00K |
| Financing Cash Flow | 13.98M | 31.20M | 34.23M | 23.18M | 43.94M | 19.49M |
Jaguar Animal Health Technical Analysis
Jaguar Animal Health Risk Analysis
Jaguar Animal Health Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $6.03M | -0.13 | -285.78% | ― | 120.67% | -456.33% | |
44 Neutral | $7.78M | -0.03 | -296.91% | ― | 15.95% | 92.33% | |
39 Underperform | $15.58M | ― | -402.19% | ― | ― | 59.81% | |
28 Underperform | $7.56M | -0.25 | -53.99% | ― | ― | 56.31% | |
28 Underperform | $2.97M | -0.02 | -340.81% | ― | ― | 94.99% | |
15 Underperform | $2.73M | -0.10 | -231.27% | ― | ― | 85.78% |
Jaguar Animal Health Corporate Events
On September 30, 2025, Jaguar Health, Inc. entered into a privately negotiated exchange agreement with a holder of royalty interest, resulting in the issuance of 286,532 shares of common stock in exchange for a $600,000 reduction in the outstanding royalty interest balance. This strategic move highlights Jaguar Health’s efforts to manage its financial obligations and optimize shareholder value, potentially impacting its financial stability and market positioning.
The most recent analyst rating on (JAGX) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Jaguar Animal Health stock, see the JAGX Stock Forecast page.
On September 28, 2025, Jaguar Health, Inc. entered into a securities purchase agreement with Brown Stone Capital Limited, agreeing to issue and sell shares and pre-funded warrants in a private placement. The proceeds from this transaction are intended for working capital, general corporate purposes, and repayment of existing convertible notes, potentially impacting the company’s financial stability and market operations.
The most recent analyst rating on (JAGX) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Jaguar Animal Health stock, see the JAGX Stock Forecast page.
On September 9, 2025, Jaguar Health, Inc. entered into securities purchase agreements with certain investors to issue and sell approximately 951 shares of Series N Perpetual Preferred Stock for around $2.38 million in a private placement, which closed on September 10, 2025. The proceeds from this transaction are intended for working capital, general corporate purposes, and repayment of certain existing notes. The Series N Preferred Stock comes with specific rights and limitations, including no dividend entitlement, voting rights alongside common stock, and liquidation preferences. The company has also set covenants to maintain compliance with reporting requirements and trading conditions.
The most recent analyst rating on (JAGX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Jaguar Animal Health stock, see the JAGX Stock Forecast page.
Jaguar Animal Health Inc. recently held its earnings call, revealing a generally positive outlook despite some financial challenges. The company highlighted significant revenue growth and successful clinical trials for its drug, crofelemer. However, these achievements were tempered by increased operational losses and a higher net loss attributable to shareholders.
On August 19, 2025, Jaguar Health held its Annual Meeting of Stockholders, where seven proposals were approved, including the election of directors and amendments to stock plans. The company also announced promising results from trials of crofelemer for gastrointestinal conditions and outlined plans for regulatory pathways and business development partnerships, potentially impacting its market strategy and stakeholder interests.
The most recent analyst rating on (JAGX) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Jaguar Animal Health stock, see the JAGX Stock Forecast page.
Jaguar Health, Inc. is a pharmaceutical company based in San Francisco, California, focused on developing and commercializing prescription and non-prescription products for both human and animal health. The company operates through two segments: human health and animal health.
On August 14, 2025, Jaguar Health, Inc. announced an amendment to its At the Market Offering Agreement, extending Lucid Capital Markets, LLC’s role as a Manager until December 31, 2025. This amendment, filed with the SEC, ensures that Lucid will continue its managerial role alongside Ladenburg Thalmann & Co. Inc. until the end of 2025, after which Ladenburg will become the sole Manager unless further extended.